Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
08 2022
Historique:
received: 15 07 2021
revised: 26 08 2021
accepted: 10 09 2021
pubmed: 7 3 2022
medline: 27 7 2022
entrez: 6 3 2022
Statut: ppublish

Résumé

According to the latest reports from WHO, the incidence of antibiotic-resistant bacterial infections is increasing worldwide, resulting in increased morbidity and mortality and a rising pressure on health-care systems. However, the development of new antibiotics is an expensive and time-consuming process, urging scientists to seek alternative antimicrobial strategies. Over the past few decades, the concept of therapeutic administration of bacteriophages (also known as phages) has gained popularity worldwide. Although conceptually promising, the widespread implementation of phage therapy in routine clinical practice is restricted by the scarcity of safety and efficacy data obtained according to the strict standards of the applicable clinical trial regulations. In this systematic review, we list clinical data published between Jan 1, 2000 and Aug 14, 2021 on the safety and efficacy of phage therapy for difficult-to-treat bacterial infections, and provide an overview of trials and case studies on the use of phage therapy in several medical disciplines.

Identifiants

pubmed: 35248167
pii: S1473-3099(21)00612-5
doi: 10.1016/S1473-3099(21)00612-5
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Review Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e208-e220

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Auteurs

Saartje Uyttebroek (S)

Department of Otorhinolaryngology, UZ Leuven, Leuven, Belgium; Experimental Otorhinolaryngology, Rhinology Research, Department of Neurosciences, KU Leuven, Leuven, Belgium.

Baixing Chen (B)

Department of Trauma Surgery, UZ Leuven, Leuven, Belgium; Locomotor and Neurological Disorders, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

Jolien Onsea (J)

Department of Trauma Surgery, UZ Leuven, Leuven, Belgium; Locomotor and Neurological Disorders, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

Fred Ruythooren (F)

Department of Trauma Surgery, UZ Leuven, Leuven, Belgium.

Yves Debaveye (Y)

Department of Intensive Care Medicine, UZ Leuven, Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

David Devolder (D)

Pharmacy Department, UZ Leuven, Leuven, Belgium.

Isabel Spriet (I)

Pharmacy Department, UZ Leuven, Leuven, Belgium; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Melissa Depypere (M)

Department of Laboratory Medicine, UZ Leuven, Leuven, Belgium; Laboratory of Clinical Bacteriology and Mycology, KU Leuven, Leuven, Belgium.

Jeroen Wagemans (J)

Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Leuven, Belgium.

Rob Lavigne (R)

Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Leuven, Belgium.

Jean-Paul Pirnay (JP)

Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Neder-over-Heembeek, Belgium.

Maya Merabishvili (M)

Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Neder-over-Heembeek, Belgium.

Paul De Munter (P)

Department of General Internal Medicine, UZ Leuven, Leuven, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Willy E Peetermans (WE)

Department of General Internal Medicine, UZ Leuven, Leuven, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Lieven Dupont (L)

Department of Pneumology, UZ Leuven, Leuven, Belgium; Respiratory Diseases and Thoracic Surgery, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.

Laura Van Gerven (L)

Department of Otorhinolaryngology, UZ Leuven, Leuven, Belgium; Experimental Otorhinolaryngology, Rhinology Research, Department of Neurosciences, KU Leuven, Leuven, Belgium; Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.

Willem-Jan Metsemakers (WJ)

Department of Trauma Surgery, UZ Leuven, Leuven, Belgium; Locomotor and Neurological Disorders, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. Electronic address: willem-jan.metsemakers@uzleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH